Rheumatology clinic

New targeted therapies for rheumatoid arthritis

Rheumatology clinic

New targeted therapies for rheumatoid arthritis

EMILY MARTIN, DAVID LIEW

Figures

© RUDISILL/ISTOCKPHOTO.COM
© RUDISILL/ISTOCKPHOTO.COM

Abstract

Better understanding of the pathophysiology of rheumatoid arthritis has led to the development of targeted biologic and small molecule (synthetic) disease-modifying antirheumatic drugs (DMARDs), including the janus kinase inhibitors.

Article Extract

Rheumatoid arthritis (RA) is the most common form of inflammatory arthritis, affecting around 1.9% of Australians.1 RA is characterised by polyarthritis, causing pain, irreversible joint damage and disability if left untreated. Treatment aims not just to improve symptoms but to induce remission or control inflammation to prevent joint injury and disability.